Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab therapeutic drug monitoring in inflammatory bowel disease
NL-OMON55193Active, not recruiting
- Sponsor
- Máxima Medisch Centrum
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of vedolizumab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis, sponsored by Máxima Medisch Centrum. Primary endpoint: Association between vedolizumab trough level and disease activity. Started May 2021; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON55193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55193.